Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with US-based Kodiak Sciences lnc. (NASDAQ: KOD) in a strategic partnership aimed at advancing the discovery of novel multi-target antibodies to treat ophthalmic diseases. The collaboration will leverage Nona Bio’s proprietary Harbour Mice fully human antibody platform, which is known for its innovative approach to antibody generation.
Leveraging the Harbour Mice Platform for Therapeutic Discovery
The Harbour Mice platform is capable of generating fully human monoclonal antibodies in both the traditional two heavy and two light chains (H2L2) format and the heavy chain-only (HCAb) format. This unique capability negates the need for additional engineering or humanization processes, streamlining the development of therapeutic antibodies. Under the terms of the agreement, Kodiak Sciences will gain the right to use both the H2L2 and HCAb Harbour Mice platforms in multiple programs focused on therapeutic antibody discovery and development. While the financial specifics of the agreement were not disclosed, the partnership signals a significant step forward in the pursuit of innovative ophthalmic treatments.
Implications for Ophthalmic Disease Treatment
This collaboration between Nona Biosciences and Kodiak Sciences highlights the potential of the Harbour Mice platform to revolutionize the development of antibodies for ophthalmic diseases. By utilizing this platform, the partnership aims to accelerate the discovery and development of new treatments, ultimately improving patient outcomes in the field of ophthalmology.-Fineline Info & Tech
